National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting, 28636-28637 [2021-11206]
Download as PDF
<![CDATA[
28636
Federal Register / Vol. 86, No. 101 / Thursday, May 27, 2021 / Notices
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Pamela Jeter, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 10J08,
Bethesda, MD 20892, (301) 435–2591,
pamela.jeter@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: May 21, 2021.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–11207 Filed 5–26–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
jbell on DSKJLSW7X2PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Biobehavioral and
Behavioral Processes Integrated Review
Group; Language and Communication Study
Section.
Date: June 21–22, 2021.
Time: 10:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Andrea B. Kelly, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3184,
MSC 7770, Bethesda, MD 20892, (301) 455–
1761, kellya2@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Small
Business: Cardiovascular Sciences.
Date: June 24–25, 2021.
Time: 9:00 a.m. to 6:30 p.m.
VerDate Sep<11>2014
17:29 May 26, 2021
Jkt 253001
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Kirk Edward Dineley,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 806E,
Bethesda, MD 20892, (301) 867–5309,
dineleyke@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Small
Business: Innovative Immunology Research.
Date: June 29, 2021.
Time: 10:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Shinako Takada, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Bethesda, MD
20892, 301–402–9448, shinako.takada@
nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Small
Business: Immune Responses and Vaccines
to Microbial Infections.
Date: June 30–July 1, 2021.
Time: 9:30 a.m. to 7:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Barna Dey, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3184,
Bethesda, MD 20892, 301–451–2796, bdey@
mail.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Bioengineering, Cellular and Circuit
Neuroscience.
Date: June 30, 2021.
Time: 9:30 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Jyothi Arikkath, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5215,
Bethesda, MD 20892, (301) 435–1042,
arikkathj2@mail.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; RFA–RM–
21–009 Cellular Senescence Network:
Technology Development and Application
(UG3/UH3).
Date: June 30, 2021.
Time: 10:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Thomas Beres, Ph.D.,
Scientific Review Officer, Center for
PO 00000
Frm 00112
Fmt 4703
Sfmt 4703
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Rm. 5201,
MSC 7840, Bethesda, MD 20892, 301–435–
1175, berestm@mail.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Infectious
Disease and Host-Pathogen Interactions.
Date: June 30, 2021.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: David C. Chang, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Bethesda, MD
20892, (301) 451–0290, changdac@
mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: May 21, 2021.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–11205 Filed 5–26–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; Early Phase Clinical Trial
Units (EPCTU): Task Area A—Administrative
and Overall Clinical Operations Support and
Concept Development (N01).
Date: June 24, 2021.
Time: 9:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
E:\FR\FM\27MYN1.SGM
27MYN1
Federal Register / Vol. 86, No. 101 / Thursday, May 27, 2021 / Notices
Health, 5601 Fishers Lane, Room 3G62
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Eleazar Cohen, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
National Institute of Allergy and Infectious
Diseases, National Institutes of Health, 5601
Fishers Lane, Room 3G62, Rockville, MD
20852, (240) 669–5081, ecohen@
niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: May 21, 2021.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–11206 Filed 5–26–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Dated: May 21, 2021.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory
Committee Policy.
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meetings
jbell on DSKJLSW7X2PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; Early Phase Clinical Trial
Units (EPCTU): Task Area D/Sample Task
Order D (N01).
Date: June 25, 2021.
Time: 9:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3G62A,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Eleazar Cohen, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
National Institute of Allergy and Infectious
Diseases, National Institutes of Health, 5601
Fishers Lane, Room 3G62A, Rockville, MD
20852, (240) 669–5081, ecohen@
niaid.nih.gov.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
VerDate Sep<11>2014
17:29 May 26, 2021
Jkt 253001
Emphasis Panel; Early Phase Clinical Trial
Units (EPCTU): Task Area E/Sample Task
Order E (N01).
Date: June 28, 2021.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3G62A,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Eleazar Cohen, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
National Institute of Allergy and Infectious
Diseases, National Institutes of Health, 5601
Fishers Lane, Room 3G62A, Rockville, MD
20852, (240) 669–5081, ecohen@
niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
[FR Doc. 2021–11212 Filed 5–26–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HOMELAND
SECURITY
[Docket Number DHS–2021–0023]
Generic Clearance for the Collection of
Qualitative Feedback on Agency
Service Delivery
Department of Homeland
Security (DHS).
ACTION: 60-Dsay notice and request for
comments; extension without change of
a currently approved Collection, 1601–
0014.
AGENCY:
The Department of Homeland
Security, will submit the following
Information Collection Request (ICR) to
the Office of Management and Budget
(OMB) for review and clearance in
accordance with the Paperwork
Reduction Act of 1995.
DATES: Comments are encouraged and
will be accepted until July 26, 2021.
This process is conducted in accordance
with 5 CFR 1320.1
ADDRESSES: You may submit comments,
identified by docket number Docket #
DHS–2021–0023, at:
Æ Federal eRulemaking Portal: https://
www.regulations.gov. Please follow the
instructions for submitting comments.
Instructions: All submissions received
must include the agency name and
docket number Docket # DHS–2021–
0023. All comments received will be
posted without change to https://
SUMMARY:
PO 00000
Frm 00113
Fmt 4703
Sfmt 4703
28637
www.regulations.gov, including any
personal information provided.
Docket: For access to the docket to
read background documents or
comments received, go to https://
ww.regulations.gov.
Executive
Order 12862 directs Federal agencies to
provide service to the public that
matches or exceeds the best service
available in the private sector. In order
to work continuously to ensure that our
programs are effective and meet our
customers’ needs, Department of
Homeland Security (hereafter ‘‘the
Agency’’) seeks to obtain OMB approval
of a generic clearance to collect
qualitative feedback on our service
delivery. By qualitative feedback we
mean information that provides useful
insights on perceptions and opinions
but are not statistical surveys that yield
quantitative results that can be
generalized to the population of study.
This collection of information is
necessary to enable the Agency to garner
customer and stakeholder feedback in
an efficient, timely manner, in
accordance with our commitment to
improving service delivery. The
information collected from our
customers and stakeholders will help
ensure that users have an effective,
efficient, and satisfying experience with
the Agency’s programs. This feedback
will provide insights into customer or
stakeholder perceptions, experiences
and expectations, provide an early
warning of issues with service, or focus
attention on areas where
communication, training or changes in
operations might improve delivery of
products or services. These collections
will allow for ongoing, collaborative and
actionable communications between the
Agency and its customers and
stakeholders. It will also allow feedback
to contribute directly to the
improvement of program management.
Improving agency programs requires
ongoing assessment of service delivery,
by which we mean systematic review of
the operation of a program compared to
a set of explicit or implicit standards, as
a means of contributing to the
continuous improvement of the
program. The Agency will collect,
analyze, and interpret information
gathered through this generic clearance
to identify strengths and weaknesses of
current services and make
improvements in service delivery based
on feedback. The solicitation of
feedback will target areas such as:
Timeliness, appropriateness, accuracy
of information, courtesy, efficiency of
service delivery, and resolution of
issues with service delivery. Responses
SUPPLEMENTARY INFORMATION:
E:\FR\FM\27MYN1.SGM
27MYN1
]]>Agencies
[Federal Register Volume 86, Number 101 (Thursday, May 27, 2021)]
[Notices]
[Pages 28636-28637]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-11206]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and Infectious Diseases; Notice of
Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The contract proposals and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the contract proposals, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Allergy and Infectious
Diseases Special Emphasis Panel; Early Phase Clinical Trial Units
(EPCTU): Task Area A--Administrative and Overall Clinical Operations
Support and Concept Development (N01).
Date: June 24, 2021.
Time: 9:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate contract proposals.
Place: National Institute of Allergy and Infectious Diseases,
National Institutes of
[[Page 28637]]
Health, 5601 Fishers Lane, Room 3G62 Rockville, MD 20892 (Virtual
Meeting).
Contact Person: Eleazar Cohen, Ph.D., Scientific Review Officer,
Scientific Review Program, Division of Extramural Activities,
National Institute of Allergy and Infectious Diseases, National
Institutes of Health, 5601 Fishers Lane, Room 3G62, Rockville, MD
20852, (240) 669-5081, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.855,
Allergy, Immunology, and Transplantation Research; 93.856,
Microbiology and Infectious Diseases Research, National Institutes
of Health, HHS)
Dated: May 21, 2021.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2021-11206 Filed 5-26-21; 8:45 am]
BILLING CODE 4140-01-P
